Skip to search formSkip to main contentSkip to account menu

tasquinimod

Known as: TASQ 
A quinoline-3-carboxamide linomide analogue with antiangiogenic and potential antineoplastic activities. Tasquinimod has been shown to decrease blood… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

ABR-215050
NCIt Antineoplastic Agent Terminology

Broader (1)

Quinolines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
PURPOSE Tasquinimod, a novel oral therapy targeting the tumor microenvironment, significantly improved progression-free survival… 
Highly Cited
2015
Highly Cited
2015
Visualization of RNA-Quadruplexes in Live Cells.
Visualization of DNA and RNA quadruplex formation in human cells was demonstrated recently with different quadruplex-specific… 
Review
2015
Review
2015
Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms.
Highly Cited
2014
Highly Cited
2014
Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
Shen, Sundstedt, and colleagues show in murine models that tasquinimod enhanced the antitumor effects of SurVaxM tumor vaccine… 
Highly Cited
2013
Highly Cited
2013
Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment.
Tasquinimod is an orally active antiangiogenic drug that is currently in phase III clinical trials for the treatment of… 
Review
2013
Review
2013
Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
Review
2012
Review
2012
Novel molecular targets for the therapy of castration-resistant prostate cancer.
Highly Cited
2010
Highly Cited
2010
Template-assembled synthetic G-quadruplex (TASQ): a useful system for investigating the interactions of ligands with constrained quadruplex topologies.
A new biomolecular device for investigating the interactions of ligands with constrained DNA quadruplex topologies, using surface… 
Highly Cited
2009
Highly Cited
2009
Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer
Background:Tasquinimod is a quinoline-3-carboxamide derivative with anti-angiogenic activity. Two open-label phase I clinical… 
Highly Cited
2006
Highly Cited
2006
Identification of ABR‐215050 as lead second generation quinoline‐3‐carboxamide anti‐angiogenic agent for the treatment of prostate cancer
Linomide, Figure 1, produces robust and consistent in vivo growth inhibition of prostate cancer models via its anti‐angiogenic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)